Welcome to our dedicated page for Mangoceuticals SEC filings (Ticker: MGRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Mangoceuticals, Inc. filings document a Nasdaq Capital Market-listed wellness telemedicine company, its MangoRx and PeachesRx brands, and securities issued to finance corporate operations. The company’s regulatory record includes Form 8-K reports on product communications, MGX-0024 data, branded GLP-1 program disclosures, litigation-related press releases, Nasdaq listing-rule notices and equity-compensation actions.
Registration statements and amendments describe the company’s securities offerings, capital structure, financial statements and risk disclosures. Other filings address common stock, warrants and pre-funded warrants, board and committee approvals, executive compensation arrangements, material events and forward-looking statement qualifications tied to Mangoceuticals’ telehealth platform, wellness products and public-company obligations.
Mangoceuticals, Inc. reported first-quarter 2026 results showing modest revenue and continued investment-driven losses. Revenue was $67,864 for the three months ended March 31, 2026, down from $109,306 a year earlier, producing gross profit of $29,001.
The company recorded a net loss of $3,403,141, compared with a $4,839,489 loss in the prior-year quarter, and a basic and diluted loss per share of $0.22. Operating expenses totaled $3,155,327, including $1,647,821 of stock-based compensation, reflecting heavy spending on growth and compensation.
Cash and cash equivalents fell to $174,562 from $1,486,338 at year-end 2025, driven by $1,311,343 of net cash used in operating activities. Total assets were $14,449,223, largely consisting of $13.8 million in acquired patents and licenses, which the company views as key to future men’s health and dermatology product opportunities.
Mangoceuticals, Inc. is a Texas-based telehealth company focused on men’s wellness, selling compounded products for erectile dysfunction, hair loss, hormone balance and weight management, plus an FDA-approved oral testosterone therapy under the MangoRx brand.
In October 2024 the company completed a 1-for-15 reverse stock split, cutting outstanding common shares from roughly 35.5 million to about 2.4 million, with options and warrants adjusted proportionately. As of March 31, 2026, it had 16,967,420 common shares outstanding and a non-affiliate market value of about $14.7 million as of June 30, 2025.
Mangoceuticals relies on related-party pharmacy Epiq Scripts and contracted telehealth providers to prescribe and fulfill its products across nearly all U.S. states. It is expanding via master distribution agreements, a $20 million patent acquisition for respiratory illness prevention technology, and a new subsidiary, Mango & Peaches, which now holds most operating assets and is majority controlled by the CEO through high-vote preferred stock.
The company also outlines a planned digital asset treasury strategy, aiming to deploy up to $100 million into Solana-based holdings through a managed structure targeting staking yields of roughly 7–8%, though no funds have yet been committed and significant additional capital would be required.
Mangoceuticals, Inc. Chief Executive Officer Jacob D. Cohen reported several compensation and financing-related transactions. He received stock options for 2,000,000 shares of common stock at an exercise price of $2.30 per share, expiring in 2035, with vesting over 18 months and acceleration on certain terminations or a change of control. He was also granted 500,000 shares of common stock as a discretionary bonus for services in 2025.
In addition, a prior $100,000 promissory note held by The Tiger Cub Trust, which is beneficially owned by Cohen as trustee, was amended into a convertible promissory note with a conversion price of $1.785 per share and 18% annual interest, and Tiger Cub received warrants to purchase 50,000 shares at $1.85 per share. Cohen reported bona fide gifts totaling 400,000 shares of common stock transferred to The Tiger Cub Trust, which the footnotes state did not change his beneficial ownership.
MANGOCEUTICALS, INC. Chief Executive Officer Jacob D. Cohen reported an option repricing approved by the Board and its Compensation Committee. On the effective date, existing stock options covering 50,000, 83,333 and 2,000,000 shares of common stock were surrendered to the company and replaced on a one-for-one basis.
The replacement options cover the same total number of underlying shares but now carry a new exercise price of $0.45 per share, which the company states exceeded the Nasdaq closing price on the effective date. All other terms of the options, including prior vesting schedules, remain unchanged. Following these changes, Cohen also reports direct holdings of 200,000 and 605,000 shares of common stock.
Mangoceuticals, Inc. approved a repricing of stock options held by Chief Executive Officer and Chairman Jacob Cohen as of March 16, 2026. The exercise price on options for 50,000 shares originally priced at $16.50, 83,333 shares at $4.80, and 2,000,000 shares at $2.30 was reset to $0.45 per share, which was the closing price of the company’s common stock on the effective date. Mr. Cohen recused himself, and the remaining disinterested directors approved the change upon recommendations from the compensation and audit committees.
The company also filed a civil lawsuit in Texas state court against its former technology consulting and software development firm, Clarity Ventures, Inc., seeking damages exceeding $73 million, exclusive of interest, costs, and attorneys’ fees. Mangoceuticals alleges Clarity failed to deliver a fully functional, HIPAA-compliant ERP and eCommerce platform, while Clarity denies these allegations and has asserted counterclaims relating to alleged unpaid invoices. Mangoceuticals states that it now operates on an internally developed telehealth and eCommerce platform and that all litigation allegations and counterclaims remain subject to the court process.
Mangoceuticals, Inc. reported new data on its proprietary antiviral compound MGX-0024 for use in poultry. In three commercial field trials in India covering approximately 29,000 broiler chickens, birds receiving MGX-0024 in drinking water had zero respiratory-related mortality, despite historical and neighboring flock data suggesting about 50% respiratory-related deaths.
A separate controlled government study using a highly pathogenic H5N1 strain found that birds pre-treated with MGX-0024 for 48 hours showed up to a 60% reduction in mortality versus untreated controls, longer time to death, and limited viral shedding. The company emphasizes these results are preliminary, subject to further validation, regulatory review, and not yet approved for veterinary use.
Mangoceuticals, Inc. reported early traction for its newly launched all-inclusive injectable testosterone replacement therapy (TRT) program, priced at $99 per month. The offer covers doctor visits, lab work and prescribed medication, delivered via the company’s telemedicine platform under the MangoRx brand.
The company highlighted that month-over-month sales for the injectable TRT program have risen 336% since its mid-December launch, while customer acquisition costs declined 54%. Management views TRT as the primary growth focus and plans to expand both injectable and oral offerings as part of a broader men’s health platform.
Mangoceuticals, Inc. reported that on February 4, 2026 it received a deficiency notice from Nasdaq because its common stock bid price had closed below $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).
The company has a 180-calendar day grace period, until August 3, 2026, to regain compliance by having its stock close at or above $1.00 for at least 10 consecutive business days. Nasdaq’s notice does not immediately affect the listing or trading of the stock, and Mangoceuticals plans to monitor its share price and consider options to address the deficiency.